Clinical trials: Atypical Ductal Hyperplasia
Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia
Ruxolitinib for Premalignant Breast Disease
This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for…
- Conditions
- Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
- Trial name
- TBCRC042 (NCT02928978)
- Testing
- Ruxolitinib
- Where
- 8 sites in United States
- Volunteers
- 84 people
- Sponsor
- Julie Nangia
Breast Atypical Ductal Hyperplasia, Breast Ductal Carcinoma In Situ
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
This phase III trial studies how well metformin hydrochloride works compared to placebo in preventing breast cancer in patients with atypical hyperplasia or in situ breast cancer.
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT01905046
- Testing
- metformin hydrochloride
- Where
- 27 sites in United States
- Volunteers
- 86 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia
Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
This phase I trial studies the side effects and best dose of bexarotene in preventing breast cancer in patients at high risk for breast cancer.
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT03323658
- Testing
- Bexarotene, Questionnaire Administration
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Atypical Ductal Hyperplasia
Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia
This research study is studying whether contrast enhanced mammography can predict if atypical ductal hyperplasia will progress to cancer. The device involved in this study is: -Contrast enhanced mammography
- Trial name
- NCT03505372
- Testing
- Contrast enhanced mammography
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute